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Risks of bleeding and thrombosis 
in intensive care unit patients 
with haematological malignancies
Lene Russell1,2* , Lars Broksø Holst1, Lars Kjeldsen3, Jakob Stensballe4,5 and Anders Perner1
Abstract 
Background: Patients with malignant haematological disease and especially those who require intensive care have 
an increased risk of bleeding and thrombosis, but none of these data were obtained in ICU patients only. We assessed 
the incidence of bleeding and thrombotic complications, use of blood products and risk factors for bleeding in an 
adult population of ICU patients with haematological malignancies.
Methods: We screened all patients with acute leukaemia and myelodysplastic syndrome admitted to a university 
hospital ICU during 2008–2012. Bleeding in ICU was scored according to the WHO grading system, and risk factors 
were evaluated using unadjusted and adjusted analyses.
Results: In total, 116 of 129 ICU patients were included; their median length of stay was 7 (IQR 2–16) days. Of these, 
66 patients (57%) had at least one bleeding episode in ICU; they bled for 3 (2–6) days and most often from lower 
and upper airways and upper GI tract. Thirty-nine (59%) of the 66 patients had severe or debilitating (WHO grade 
3 or 4) bleeding. The median platelet count on the day of grade 3 or 4 bleeding was 23 × 109 per litre (IQR 13–39). 
Nine patients (8%) died in ICU following a bleeding episode; five of these had intra-cerebral haemorrhage. Platelet 
count on admission was associated with subsequent bleeding (adjusted odds ratio 1.18 (95% CI 1.03–1.35) for every 
10 × 109 per litre drop in platelet count, p = 0.016). Eleven of the 116 patients (9%) developed a clinically significant 
thrombosis in ICU, which was the cause of death in four patients. The median platelet count was 20 × 109 per litre 
(15–48) at the time of thrombosis. The patients received a median of 6 units of red blood cells, 1 unit of fresh frozen 
plasma and 8 units of platelet concentrates in ICU.
Conclusions: Severe and debilitating bleeding complications were frequent in our ICU patients with haematologi-
cal malignancies, but thrombosis also occurred in spite of low platelet counts. Platelet count on ICU admission was 
associated with subsequent bleeding.
Keywords: Bleeding, ICU, Intensive care, Haematology, Leukaemia, Myelodysplastic syndrome, Thrombosis, Sepsis, 
Transfusion
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Background
Acute leukaemia and myelodysplastic syndrome are dev-
astating diseases that, in worst cases, involve life-threat-
ening complications such as bleeding, sepsis, respiratory 
failure and renal failure, often caused by disease or treat-
ment-related pancytopenia [1–4]. Some patients will 
require admission to the intensive care unit (ICU), and 
although the mortality for these patients appears to have 
declined over the last two decades, it continues to be very 
high [4–6].
Patients with malignant haematological disease and 
especially those who require intensive care have an 
increased risk of bleeding and thrombosis [7–11], but 
none of the studies were in ICU patients only. The pre-
vention of haemorrhage and thrombosis is a challenging 
task as the risk of both complications is likely to increase 
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in patients with sepsis [12–14], which is very frequent in 
ICU patients with malignant haematological disease [2, 
5]. Thrombocytopenia increases risk of bleeding com-
plications [11], and platelet transfusions remain the cor-
nerstone in treatment and prevention of bleeding [15, 
16]. Large multicentre studies on prophylactic platelet 
transfusions in thrombocytopenic non-ICU patients have 
shown that a restrictive prophylactic platelet transfusion 
strategy is likely to be safe [9], although the degree of 
restrictiveness is still controversial [10]. The vast major-
ity of patients with malignant haematological disease are 
receiving blood products [17] so complications second-
ary to transfusions are also likely [14].
Because of these complexities and the lack of ICU data, 
we aimed to assess the following: incidence of bleed-
ing, time to onset, risk factors for bleeding, transfusion 
requirements, risk of thrombotic complications and asso-
ciation with death in an ICU population of patients with 
haematological malignancies.
Methods
All patients with acute myeloid leukaemia (AML), acute 
lymphoblastic leukaemia (ALL) and myelodysplastic 
syndrome (MDS) admitted to the general ICU at Copen-
hagen University Hospital, Rigshospitalet, between 1 
January 2008 and 3 December 2012 were identified 
through the local electronic ICU database (CIS, Daintel, 
Copenhagen). All electronic files including computed 
tomography (CT) reports, ultrasound scan reports and 
autopsy reports, when available, were reviewed. Use of 
pro-coagulant and anti-thrombotic medications was col-
lected from the electronic medication charges and blood 
transfusion usage from the Blood Bank database.
Bleeding and thrombosis data were reviewed every 
single day of the ICU admission. The electronic patient 
chart system has a pre-defined section for coagulation 
issues, prompting the physician to prospectively fill out 
data on coagulation/bleeding/thrombosis status on a 
daily basis. Bleeding was graded retrospectively accord-
ing to the WHO criteria [18]. The WHO grading sys-
tem, which is the most common method for categorising 
bleeding severity in platelet transfusion trials [10, 19, 20], 
categorises bleeding episodes as grade 1 (mild), grade 
2 (moderate), grade 3 (severe, requiring red blood cell 
(RBC) transfusion within 24 h) or grade 4 (debilitating or 
life-threatening). Details of grading system are presented 
in Additional file 1: Table S1.
The blood transfusion products used were stand-
ard pre-storage leuko-reduced RBC suspended in 
saline–adenine–glucose and mannitol, fresh fro-
zen separated donor plasma (with 70% of coagula-
tion factors preserved) and platelet concentrates from 
four donors. All transfusions were type/cross-match 
compatible. One unit RBC  =  245  ml, one unit fresh 
frozen plasma (FFP)  =  275  ml, and one unit platelet 
concentrates = 350 ml.
Daily platelet counts were done with an automated hae-
matology analyser (Sysmex XE-500, Denmark). Throm-
bocytopenic patients with bleeding had platelet counts 
analysed twice a day. Platelet counts of less than 10 × 109 
per litre were manually counted.
Simplified Acute Physiology Score (SAPS) II and the 
Sequential Organ Failure Assessment (SOFA) score were 
calculated using the worst value for that variable during 
the first 24 h of ICU admission [21, 22].
Statistical analysis
Qualitative data were analysed using Mann–Whitney 
test for nonparametric data. For categorical data, the 
Chi-square test was used, and in the few cases when 
expected values were less than 5, Fisher’s exact test was 
used. The odds ratio (OR) was calculated where appro-
priate and expressed together with 95% confidence 
interval (CI). Risk factors for bleeding with a p value of 
less than 0.10 in unadjusted analyses were included in a 
multiple logistic regression analysis. Survival analysis of 
bleeding within the first 3 days in the ICU was conducted 
using the Kaplan–Meier method, and log-rank test was 
used to compare the survival curves. The linear assump-
tions for qualitative data included in the regression mod-
els were tested with linear splines with knot points at the 
quartiles. We used SAS version 9.4 (USA) and GraphPad 
Prism 6.00 for OS (USA) for the analyses and considered 
any differences statistically significant if the two-sided p 
value was less than 0.05.
Results
Clinical and general characteristics
One hundred and twenty-nine consecutive patients with 
ALL, AML or MDS were admitted during 2008–2012 and 
screened for inclusion; 13 patients were excluded from 
the study due to post-procedural observation (n  =  11) 
and observation less than 24-h due to allergic reactions 
(n = 2). Thus, 116 patients were included (Table 1).
The primary reasons for ICU admission were respira-
tory failure and severe sepsis/septic shock; 109 (94%) of 
the patients fulfilled the criteria for sepsis, severe sepsis 
and septic shock according to the International Sepsis 
Definitions of 2003 [23], and 82 patients (71%) had shock 
on admission. The median admission SAPS II and SOFA 
scores were 58 (interquartile range (IQR) 50–75) and 12 
(9–14), respectively.
Bleeding and platelets
In total, 66 patients (57%) had one or more bleed-
ing episodes during the ICU stay (WHO grade 1–4). 
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The median number of days with bleeding was 3 (IQR 
2–6). One-third (n  =  38, 33%) of the patients had a 
bleeding episode during the first 24  h in ICU, and 49 
patients (42%) had an episode during the first 5 days. The 
116 included patients spent a total of 1728  days in the 
ICU and of these, 333 (19%) were days when bleeding 
occurred.
The majority of the patients bled from more than one 
location; only 17/66 (26%) bled from one location only 
(Table 2). The most common locations were lower/upper 
airways and upper gastrointestinal (GI) tract. Respiratory 
tract bleedings were more common among mechanically 
ventilated patients [49/101 (49%) vs. 1/15 (7%)]; however, 
three patients were intubated and mechanically venti-
lated due to bleedings in the airways. Six patients devel-
oped intracranial bleeding (ICH). One of the patients 
with ICH had severe leukocytosis (WBC  >  100  ×  109 
per litre) with predominance of myeloblasts, known to 
be associated with increased risk of intracranial haemor-
rhage [24].
More than half of the patients with bleeding had a 
severe (WHO grade 3) or debilitating (WHO grade 4) 
bleeding episode (39 patients, 59%). There was no sig-
nificant difference in the number of bleeding complica-
tions when stratifying for ALL, AML and MDS patients 
(p = 0.67), and haematopoietic stem cell transplantation 
(HSCT) patients had similar numbers of bleeding com-
plications to non-HSCT patients (p = 0.86) (Fig. 1).
Patients’ median platelet count at ICU admission was 
29  ×  109 per litre (IQR 18–48), and the majority (88 
patients, 76%) were severely thrombocytopenic at admis-
sion with platelet counts < 50 × 109 per litre.
The platelet count on admission was the only variable 
associated with subsequent bleeding (Fig.  2, Table  3). 
The adjusted OR for bleeding within the first 5  days in 
the ICU was 1.15 (95% CI 1.00–1.33) for every drop in 
platelet count by 10 × 109 per litre, p = 0.058 and 1.18 
(1.03–1.35), p  =  0.016 for bleeding in the ICU. The 
median platelet count on the first bleeding day was 
21 × 109 per litre (IQR 15–31), and the median platelet 
count on the day of having a severe or debilitating bleed-
ing episode (WHO grade 3 or 4) was 23 × 109 per litre 
(13–39). In patients with subsequent bleeding in the 
ICU, we found that the individual differences in platelet 
counts on the first day of bleeding compared to at admis-
sion were minor [median difference 0 (IQR 0–0), mean 
− 3.8 × 109(min–max: − 98 − (+ 28)).].  
Mortality
Within the first week in ICU, 33 of the 116 patients (28%) 
had died and in total 64 (55%) of the patients died in the 
ICU. The 30-day, 90-day and 1-year mortality was 60, 72 
and 86%, respectively.
Table 1 Characteristics of the study population (N = 116)
Values are number (%) or median (IQR)
AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, MDS 
myelodysplastic syndrome, CML chronic myeloid leukaemia, CMML chronic 
myelomonocytic leukaemia, SAPS II Simplified Acute Physiology Score, SOFA 
Sequential Organ Failure Assessment score, WBC white blood cell
a According to the International Sepsis Definitions 2003 [23]
b SOFA score at admission minus score values given for platelets count (× 109 
per litre): ≥ 150: score = 0; ≥ 150: score = 0; < 150: score = 1; < 100: score = 2; 
< 50: score = 3; < 20: score = 4
Baseline characteristics
 Age 60 (48–66)
 Female 52 (45)
 Diagnosis
  ALL 15 (13)
  AML 75 (65)
  MDS 26 (22)
 Time from leukaemia diagnosis to ICU admission
  Less than 3 months 35 (30)
  3–6 months 12 (10)
  6–12 months 20 (17)
  More than 12 months 50 (43)
 Chemotherapy within 6 weeks prior to admission 76 (66)
 Haematopoietic Stem Cell Transplantation (HSCT) 43 (37)
 Graft-versus-host reaction 20 (17)
 Relapse after having received treatment 20 (17)
 Transformation from other haematological malignancy 18 (16)
  From MDS to AML 10 (9)
  From CML to AML 2 (2)
  From CMML to AML 2 (2)
  From Mb. Waldenstrom to AML 1 (1)
 Respiratory or systemic fungal infection 19 (16)
 Primary reason for ICU admission
  Respiratory failure 59 (51)
  Septic shock/severe sepsis 39 (34)
  Bleeding 3 (3)
  Severe graft-versus-host reaction 3 (3)
  Other 13 (11)
 WBC count at admission (× 109 per litre) 3 (0.2–11)
ICU characteristics
 Sepsisa 109 (94)
  Sepsis 9 (8)
  Severe sepsis 18 (15)
  Septic shock 82 (71)
 Mechanical ventilation in ICU 101 (87)
 Vasopressor in ICU 95 (82)
 Renal replacement therapy in ICU 42 (37)
 Emergency surgery immediately before or during ICU 
stay
3 (3)
 SAPS II 58 (50–75)
 SOFA (admission) 12 (9–14)
 SOFA (admission) without platelet  scoreb 8 (6–11)
 SOFA (maximum) 14 (11–17)
 Length of ICU stay, days 7 (2–16)
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Nine patients (8%) died in ICU following an acute 
bleeding episode; five of these had ICH, three had pul-
monary bleeding and one a large post-operative bleed-
ing after acute hemi-colectomy for bowel ischaemia. The 
unadjusted 30-day and 1-year mortality was higher in 
bleeding vs. non-bleeding patients (68 vs. 50%, p = 0.047 
and 92 vs. 78%, p =  0.022), but the Kaplan–Meier sur-
vival analysis curve stratified by bleeding or not within 
the first 3 ICU days did not indicate any difference 
between the two groups (Fig. 3). Including age and SOFA 
score at admission in the survival analysis, the HR for 
death in bleeding versus non-bleeding patients was 1.28 
(95% CI 0.79–2.1, p = 0.31). 
Transfusions
Due to lack of Danish national identification numbers, 
four patients did not have their transfusion data regis-
tered in the Blood Bank database. Of the remaining 112 
patients, 100 patients (89%) received one or more trans-
fusions of RBC, FFP or platelets concentrates during 
their ICU stay. The 112 patients received a total of 3561 
units of blood products, and half of the units (1749 units, 
49%) were given within the first week in ICU. Only four 
patients with bleeding did not receive any transfusions at 
all; two patients had large intracranial bleedings that was 
the immediate cause of death, and two had minor bleed-
ings not requiring transfusions. The amount of transfu-
sions increased on the days leading up to a grade 3 or 4 
bleeding episode (Fig. 4).
Red blood cell transfusions
Ninety patients (80%) had at least one RBC transfu-
sion during their ICU stay and received median 6 (IQR 
1–13) units; 32/90 (36%) did not have any signs of clinical 
bleeding during the ICU stay.
Bleeding patients received a median of 10 (4–20) units 
of RBC during ICU stay as compared with 2 (0–7) units 
in non-bleeding patients (p = < 0.0001) or 0.78 unit/ICU 
day for bleeding patients versus 0.30 unit/ICU day for 
non-bleeding patients (p = 0.0003).
Fresh frozen plasma transfusions
Sixty of the 112 patients (54%) received a median 1 unit 
of FFP during ICU stay (IQR 0–4 units). The median 
amount of FFP administered to bleeding patients was 4 
(0–12) units while in ICU or 0.28 units/ICU day. Twenty-
seven per cent of the patients who received FFP did not 
have any signs of clinical bleeding during the ICU stay.
Platelet transfusions
Ninety of the 112 patients (80%) received a median 8 
(IQR 2–23) units of platelets during ICU stay equalling 
a median of 2800 (700–8050) ml of platelets; 32 (36%) 
did not have any signs of clinical bleeding during the ICU 
stay. Patients with platelets < 50 × 109 per litre received 
a median of 10 (4–28) units during ICU or 1.7 (0.8–2.3) 
units/day.
Bleeding patients received a median of 22 (8–39) units 
of platelets during ICU stay as compared with 2 (0–7) 
units for non-bleeding patients (p < 0.0001) or 1.8 unit/
day for bleeding patients versus 0.5 unit/day for non-
bleeding patients (p < 0.0001).
Table 2 Anatomical site of bleeding
All values are number (%)
Many patients bled from more than one site: 17 (26%) bled from one site only; 
25 (38%) bled from two sites; 12 (18%) bled from three sites; 12 (18%) bled from 
four or more sites
a Upper airway bleeding included bleedings from the nose, mouth, pharynx 
and larynx
b Skin bleedings included petechia, purpura and ecchymosis
c Subconjunctival bleeding
d The biopsy sites were: liver (N = 2), skin and bone marrow (pelvis)
e Other sites included vaginal (non-menstrual) bleedings, pelvic bleedings, a 
pericardial bleedings and a bleeding from spontaneous spleen rupture
Intracranial bleeding 6 (5)
Upper airway  bleedinga 23 (20)
Lower airway bleeding 41 (35)
Upper gastrointestinal bleeding 22 (19)
Lower gastrointestinal bleeding 14 (12)
Skin  bleedingsb 17 (15)
Bleeding from sites of vascular catheters 13 (11)
Urinary tract 10 (9)
Eyesc 1 (1)
Post-biopsyd 4 (3)
Post-surgical bleeding 3 (3)
Eyesc 1 (1)
Other  sitese 7 (6)
0 20 40 60 80 100 120
All patients
AML
MDS
ALL
HSCT
Number of patients
No bleeding
WHO grade 1
WHO grade 2
WHO grade 3
WHO grade 4
Fig. 1 Bleeding complications during ICU stay. No significant dif-
ference was seen in number of bleedings complications between 
the different diagnoses or in patients with haematopoietic stem cell 
transplantation (HSCT). ALL acute lymphoblastic leukaemia, MDS 
myelodysplastic syndrome, AML acute myeloid leukaemia
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Thrombosis
Eleven of the 116 patients (9%) developed a clinically sig-
nificant thrombotic event (Table 4), which was the cause 
of death in four patients. The median platelet count was 
20 × 109 per litre (IQR 15 − 48 × 109 per litre) at the time 
of thrombosis. Six of the 11 patients with thrombosis also 
had bleeding episodes during their ICU stay. Patients 
with thrombosis had the same amount of RBC and 
slightly more platelets/day than patients without throm-
bosis. Nine (82%) of the patients with thrombosis had 
received plasma transfusion as compared with 50/101 
(50%) of the patients without thrombosis (p = 0.06) and 
those with thrombosis received more units of FFP per 
ICU day than patients without thrombosis (0.5 unit/day 
(0.1–1.5) vs. 0.02 (0–0.62) unit/day, p = 0.053).
Thrombosis prophylaxis
Forty-seven patients (41%) received the low molecu-
lar weight heparin (LMWH) enoxaparin in prophylac-
tic doses during the ICU stay. There was no difference 
in bleeding complications between patients receiving 
LMWH and those who did not (p =  0.39). None of the 
patients received anti-platelet treatments when admitted 
to the ICU or during the ICU stay.
Among the 88 patients with platelet levels less than 
50  ×  109 per litre on admission, 30 patients (34%) 
received LMWH and 58 (66%) did not. No difference in 
bleeding complications was seen between these groups 
of patients either (p = 0.13). Four of the 11 patients with 
thrombotic events had received prophylactic LMWH at 
the time of the event.
<10 10 - 19 20 - 29 30 - 39 40 - 49 50 - 69 70 - 99 100 - 149 >150
0
10
20
30
Platelet count on ICU admission (x109 per liter)
Nu
m
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nt
s
No bleeding
WHO 1
WHO 2
WHO 3
WHO 4
Fig. 2 Bleeding complications at different platelet levels. This figure shows the range of platelet level at ICU admission across our patient popula-
tion and frequency of bleeding complications in ICU graded according to WHO, in which bleeding episodes are categorised as grade 1 (mild), grade 
2 (moderate), grade 3 (severe; requiring red blood cell (RBC) transfusion within 24-h) or grade 4 (debilitating or life-threatening)
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Pro‑coagulant drugs and vitamin K
Pro-coagulant drugs were administered to 11 patients 
(9%); 8 patients had vitamin K administered (7%), and 2 
had so without prior bleeding. Both these patients devel-
oped large thrombi, which were the immediate cause of 
death. Nine patients received tranexamic acid.
Discussion
This study confirmed that a high percentage of ICU 
patients with acute leukaemia and myelodysplastic syn-
drome are subject to bleeding. Low platelet count at 
ICU admission was associated with bleeding. Despite 
bleeding being the cause of death in some patients, 
bleeding was not associated with time to death after 
adjustments for known risk factors. The patients were 
transfused with a large amount of blood products 
compared to haematological non-ICU patients [9, 10]. 
This is not surprising, given the inherent bone mar-
row failure of either the disease itself or its treatment 
with chemotherapy, which 66% of patients had received 
less than 6  weeks prior to ICU admission. Thrombotic 
events also occurred in some patients despite low plate-
let counts.
It is well known that patients with haematological can-
cer receiving chemotherapy or undergoing HSCT have 
an increased risk of bleeding. The number of bleeding 
events has been studied as primary end-point in sev-
eral large, multicentre platelet transfusion trials per-
formed outside the ICU. In the PLADO (Platelet Dose) 
trial, including 1272 patients undergoing chemotherapy 
or HSCT, 67% had a bleeding episode before leaving the 
hospital or within 30 days [9]. In the TOPPS study (Trial 
Table 3 Risk factors at ICU admission for bleeding in unadjusted and adjusted analyses
Bold indicates significant results (p < 0.05)
n/a not applicable
a One patient lost at 1-year follow up
b Chemotherapy within 6 weeks of ICU-admission
c Leukopenia at ICU admission defined as white blood cell (WBC) count < 2 (missing data = 1)
d Confirmed systemic or respiratory fungal infection
e Mechanical ventilation on day one in ICU
f Low molecular weight heparin (enoxaparin 20–40 mg daily)
g Logistic regression analysis with bleeding as outcome and chemotherapy, WBC count and platelet count as co-variates
h Platelet count OR for every decrease in platelet count by 10 × 109 (at admission)
Unadjusted analyses Bleeding within 5 days of admission Bleeding in  ICUa
No. (%) OR (95% CI) p value No. (%) OR (95% CI) p value
Acute lymphatic leukaemia 5 (36) 1.37 (0.43–4.36) 0.60 7 (50) 1.37 (0.44–4.20) 0.58
Acute myeloid leukaemia 33 (44) 0.82 (0.38–1.77) 0.82 45 (60) 0.70 (0.33–1.51) 0.36
Myelodysplastic syndrome 11 (40) 1.08 (0.45–2.60) 0.85 14 (52) 1.31 (0.55–3.10) 0.55
Recent  chemotherapyb 39 (51) 3.16 (1.36–7.36) 0.006 49 (64) 2.45 (1.12–5.37) 0.02
HSCT 15 (35) 0.61 (0.28–1.33) 0.22 24 (56) 0.93 (0.44–2.00) 0.86
Leukopenia at  admissionc 31 (56) 3.09 (1.43–6.64) 0.004 35 (64) 1.69 (0.80–3.56) 0.16
Fungal  infectiond 10 (48) 1.31 (0.51–3.37) 0.58 14 (67) 1.65 (0.61–4.47) 0.32
Renal replacement therapy 11 (48) 1.33 (0.53–3.32) 0.54 13 (57) 0.98 (0.39–2.46) 0.97
Mechanical  ventilatione 28 (41) 0.90 (0.43–1.90) 0.78 39 (57) 1.05 (0.50–2.21) 0.91
Use of  LMWHf 9 (29) 0.49 (0.19–1.19) 0.11 16 (52) 0.81 (0.35–1.86) 0.62
Median (IQR) OR (95% CI) p value Median (IQR) OR (95% CI) p value
Age 58 (48–65) 1.00 (0.97–1.03) 0.73 59 (45–66) 1.00 (0.95–1.03) 0.97
Platelet count at admission 22 (15–31) 1.16 (1.03–1.32)f 0.001 24 (15–35) 1.14 (1.03–1.26)f 0.004
SOFA-score at admission 12 (9–14) 1.05 (0.96–1.15) 0.14 12(9–14) 1.03 (0.95–1.13) 0.34
Adjusted  analysesg Bleeding within 5 days Bleeding in ICU
Median(IQR) OR (95%CI) p value Median (IQR) OR (95% CI) p value
Recent chemotherapy n/a 2.27 (0.93–5.56) 0.07 n/a 1.70 (0.70–3.95) 0.24
White blood cell count 2.8 (0.2–11) 1.01 (0.99–1.02) 0.39 1.2 (0.1–8.5) 1.02 (1.00–1.04) 0.07
Platelet  counth 22 (15–31) 1.15 (1.00–1.33) 0.058 24 (15–35) 1.18 (1.03–1.35) 0.016
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of Prophylactic Platelets), including 598 patients under-
going chemotherapy for haematological cancer or HSCT, 
47% of the 598 patients bleed within 30 days [10]. Both 
studies had low platelet levels as one of the inclusion 
criteria.
Likewise, in a German platelet dose study, 391 patients 
undergoing HSCT or intensive chemotherapy for AML 
were randomised to receive platelets either when bleed-
ing or when platelet counts were less than 10  ×  109 
per litre. Patients were only followed as long as platelet 
counts were less than 20  ×  109 per litre. In the HSCT 
group, grade 3 bleedings were rare and grade 4 bleedings 
non-existent. In the leukaemia group, 15 patients had 
non-fatal haemorrhages, including six with minor cere-
bral bleeds. Two fatal intracranial bleeds were registered, 
both in the group receiving platelets when bleeding [16].
Our study population was small compared to the 
three trials described above, but overall we found the 
same number of bleeding complications. In other words, 
despite our patients having considerably shorter observa-
tion periods the same incidence of bleeding was found. 
We also found that our patients had longer bleeding epi-
sodes. The median number of days with bleeding in the 
PLADO study was one day, whereas our patients bled for 
3 days. Importantly, in our study population, more than 
half of the bleedings were severe or debilitating and 8% 
had fatal bleedings. In contrast, in PLADO 10% of the 
patients had WHO grade 3 or 4 bleedings and only one 
patient died from bleeding. In TOPPS, 1% (7 patients) 
had grade 3 or 4 bleeding episodes and none died from 
bleeding.
Patients with lower platelet levels did have a higher fre-
quency of bleeding complications. Most patients received 
prophylactic platelet transfusions when platelet levels 
fell below 20 × 109 per litre, although the platelet levels 
at which the individual patient was transfused was at 
the clinicians’ discretion. The proportion of severe and 
debilitating bleedings (WHO grade 3–4) did not decrease 
as might have been expected at increasing platelet lev-
els, which probably explains why platelet levels did not 
Fig. 3 Time to death showed as Kaplan–Meier survival curves in bleeding and non-bleeding patients. The log-rank score for bleeding was 1.74 
(p = 0.19) and the hazard ratio (HR) for patients with bleeding as compared to non-bleeders was 1.37 (95% CI 0.86–2.19). Survival curves are pre-
sented with 95% confidential intervals
0
1
2
3
4
5
6
7
Day - 6 Day - 5 Day - 4 Day -3 Day -2 Day-1 Bleeding
No. (units)
FFP
RBC
Plt
Fig. 4 Blood transfusions given the days before a WHO grade 3–4 
bleeding episode. This figure shows the median amount of blood 
products given during the days leading up to a major bleeding. FFP 
fresh frozen plasma, RBC red blood cells, Plt platelet concentrate
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influence survival in our population. However, use of 
platelet and RBC transfusions was increasing in the days 
leading up to a severe bleeding, which might indicate 
that increasing platelet dependency and minor bleedings 
could be warning signs of severe/debilitating bleeding.
We also analysed biochemical coagulation parameters 
and calculated the disseminated intravascular coagula-
tion (DIC) scores according to the definition by the Inter-
national Society of Thrombosis and Haemostasis (ISTH) 
[25]. Among these other markers of coagulation (Inter-
national normalised ratio (INR), activated pro-thrombin 
time (APTT), anti-thrombin, D-dimer and fibrinogen) 
only INR was weakly associated with subsequent bleed-
ing (odds ratio 2.91 for bleeding within 24  h, 95% CI 
1.01–8.43, p = 0.048). The DIC score was neither associ-
ated with bleeding nor thrombosis. None of the biochem-
ical parameters had any predictive value with regard to 
bleeding in these patients as described elsewhere [26].
The majority of bleedings in our ICU started within 
the first 5  days. Several bleedings were severe and in 
nine patients (8%) the direct cause of death, thereby con-
tributing to the high mortality. More than half of the 
patients died in ICU, and the 30-day mortality was 60%. 
This is similar to the mortality rates described by Pène 
et al. in critically ill HSCT patients [27], but higher than 
described in some other studies of critically ill haema-
tology patients. However, our population differs from 
some of the previous studies [3, 5, 28–31] in that the vast 
majority were mechanically ventilated (87%) and received 
vasopressor (82%). In most other studies, the ratio of 
mechanically ventilated patients has been considerably 
lower, in some less than 50% [3, 30–32].
So why are our patients bleeding more? Sepsis-induced 
coagulopathy causes bleeding in ICU patients [33], so 
the risk of bleeding is likely to be increased in leukae-
mia patients with sepsis and a large proportion of our 
patients indeed had sepsis at ICU admission. A low plate-
let count has been associated with adverse outcome in a 
general population of ICU patients [32, 34–37] although 
thrombocytopenia as a determinant of severe bleeding in 
ICU remains unclear. Several studies have assessed the 
risk of bleeding in ICU patients with thrombocytopenia 
[34, 37–39], and most have found a higher risk of bleed-
ing in patients with lower platelet counts [36, 38, 40] with 
the exception of one study, which found that sepsis was 
the single variable associated with bleeding in multivari-
ate analysis [41]. However, none of these studies were in 
haematological patients only.
Although the incidence of bleeding in medical ICU 
patients without haematological malignancies is lower, 
the exact numbers are not certain, as haematological 
patients often are included in the general ICU popula-
tions. The prospective multicentre Scandinavian Starch 
for Severe Sepsis/Septic Shock (6S) trial [42], which 
included 798 general ICU patients with severe sepsis, had 
severe bleeding (defined as clinical bleeding that required 
3 or more units of packed red cells within 24  h) as one 
of the pre-defined outcomes. In 6S, 19% of the patients 
had a bleeding episode and 8% had severe bleeding [43]. 
However, 35% of the patients had surgery prior to ICU 
admission. Among the patients without prior surgery, 
only 16% had a bleeding episode and 6% had severe 
bleeding. Haematological patients were included in this 
study, constituting 9% of the total study population.
Some of our patients also had thrombotic events in 
spite of low platelet counts, which was the cause of death 
in four patients. The patients with thrombosis also had 
low platelet counts on the day of the thrombus, and sev-
eral of them had one or more bleeding episodes before 
the thrombotic episode. All except one of the thrombotic 
events in our study were in patients with AML. Patients 
with acute leukaemia have an increased risk of thrombo-
sis that may be as high, or even higher than in patients 
with solid tumours [44, 45]. There are several reasons 
why thrombocytopenic leukaemia patients still have an 
increased risk of thrombosis [8, 46, 47]:  Leukaemic cells 
express pro-coagulant mediators including tissue factor 
[48, 49], produce pro-inflammatory and pro-coagulant 
Table 4 Thrombotic events in ICU
Data are in number (%)
AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, MDS 
myelodysplastic syndrome, LMWH low molecular weight heparin
a Enoxaparin 20–40 mg daily in ICU before thrombotic event
b Site of thrombi: 1. spleen (post-mortem finding); 2. thalamus (MRI finding)
c Site of thrombi: 1. inferior vena cava; 2. brain (multiple sites)
No. of thrombotic events—no (%) 11 (9)
Site of thrombosis
 Brain 5
 Arm, fingers, toes 2
 Liver veins 2
 Spleen (post-mortem finding) 1
 Inferior vena cava 1
Haematological diagnosis
 AML 10
 ALL 1
 MDS 0
Severe sepsis/septic shock—no (%) 11 (100)
Death directly related to thrombosis—no 4
Bleeding prior to thrombotic event 3
Bleeding after thrombotic event 3
LMWHa 4
Drugs given prior to thrombotic event
 Tranexamic acid 2 b
 Vitamin K 2 c
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cytokines [50, 51], release leukaemia cell derived micro-
particles into the blood stream which are expressing 
tissue factor on the surface [52] and directly activate 
platelets [53, 54]. The rapid cell death induced by chemo-
therapy further increases the release of pro-coagulant 
factors into the blood stream [50]. Furthermore, all our 
patients had central venous catheters which is a likely risk 
factor for thrombosis in patients with acute leukaemia, 
although the incidence has varied in different studies and 
no studies have been in ICU patients only [55–57].
Preventing thromboembolic complications in throm-
bocytopenic patients with haematological malignancy 
is indeed complicated due to the high risk of bleed-
ing. There are no available guidelines for prevention of 
thrombosis in acute leukaemia patients outside the ICU 
setting, and in ICU the risk is likely to be even more 
increased due to immobilisation, use of vasopressors and 
sepsis [58, 59]. To our knowledge, no randomised trials 
on thrombosis prophylaxis in leukaemia patients have 
been made. A prospective multicentre study on the inci-
dence of thrombosis in non-ICU haematological patients 
with central venous catheters found no increase in bleed-
ing in the 14% of patients receiving thrombosis prophy-
laxis [55]. However, even though thrombosis prophylaxis 
was not found to increase the number of bleeding epi-
sodes, the incidence of thrombosis was not reduced. 
Similar results were found in a retrospective study of 
central venous catheters in AML patients [57] as well as 
in a study of low-dose warfarin prophylaxis in oncology 
patients [60]. In our study, 47 patients (41%) received 
enoxaparin as thrombosis prophylaxis during the ICU 
stay. No increase in bleeding events was observed among 
these patients.
Our patients received large amounts of blood products. 
Severely thrombocytopenic patients would be expected 
to bleed more and therefore receive more RBC transfu-
sions, but this was not the case. Bleeding patients did, for 
obvious reasons, receive more blood products than non-
bleeding patients, but it is worth noticing that 36% of the 
patients who received RBC transfusion and 27% of the 
patients who received fresh frozen plasma did not have 
any signs of clinical bleeding.
This study has several limitations. Due to its retro-
spective nature, there is a risk of underestimating the 
occurrence of minor bleedings. Furthermore, this is a 
single-centre study and it may be that the results are 
different in other centres. Most importantly, we cannot 
make any inferences about cause and effect because of 
the observational design, in particular as the time at risk 
of bleeding for any patient is related to the time spent in 
ICU, and as such it is difficult to analyse any associations 
to mortality.
The strength of this study is the high availability of 
data achieved by using three separate databases linked 
using the patients’ unique identification number. We also 
included a relatively homogenous group of patients with 
only  three acute haematological diagnoses, and where 
the majority had sepsis, required mechanical ventilation 
and had received chemotherapy  within 6  weeks of ICU 
admission. We had few exclusions and full follow-up of 
all included patients.
Conclusions
ICU patients with acute leukaemia and MDS had a high 
risk of severe, debilitating and fatal bleeding episodes in 
the ICU and lower platelet counts appeared to be a risk 
factor for bleeding. Preventing severe bleeding episodes 
appears to be crucial, and close daily monitoring of minor 
bleedings and increasing platelet dependency might aid 
this goal. Further research is warranted in order to avoid 
debilitating and fatal bleeding without increasing the risk 
of thrombosis. It seems worthwhile to test the benefits 
and harms of therapeutic interventions, e.g. higher plate-
let trigger values in high-risk patients and alternatives to 
platelet transfusions to prevent bleeding as well as the 
benefits/risk of thrombosis prophylaxis in thrombocyto-
penic ICU patients with acute leukaemia and MDS.
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